India's Gland Pharma rises after US FDA approval for drug application

Gland Pharma

08/01/2026 04:07

** Shares of Gland Pharma GLAD.NS rise as much as 4.8% 1,790.4 rupees
** Pharma co gets approval from the United States Food and Drug Administration (USFDA) for abbreviated new drug application filed for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%
** Adds, product is indicated for treatment of ocular itching associated with allergic conjunctivitis
** Stock last up 1.7%; top pct gainer on the Nifty Pharma index .NIPHARM, which is down 0.6%
** More than 419,000 shares traded, 3.8x the 30-day moving avg
** Mean rating of stock is "hold"; their median PT is 2,050 rupees - data compiled by LSEG
** GLAD fell 3.2% in 2025

 (Reporting by Meenakshi Maidas in Bengaluru)

 ((meenakshi.maidas@thomsonreuters.com;))